by Lisa Chamoff
, Contributing Reporter | July 27, 2020
From the July 2020 issue of HealthCare Business News magazine
The company has improved the algorithm for the synthetic 2D image on its Planmed Clarity 3D digital breast tomosynthesis system
“It looks like a normal 2D image so the radiologist doesn’t have to look at something different,” said Jukka Erkkilä, clinical and product management director of Planmed Oy. “The radiologists really prefer it and sometimes they prefer it over the normal 2D.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Planmed also had a software update in December that improved post processing for tomosynthesis and stereotactic biopsy.
“It improves tissue separation and also sharpness,” Erkkilä said. “Microcalcifications are clearer.”
The update also provides support for AccuBoost brachytherapy.
Formerly known as Quantitative Insights, the company was acquired by Paragon Biosciences, a Chicago-based incubator, in June of 2019.
Since then, Qlarity Imaging has made upgrades to the usability and efficiency of its QuantX AI-based decision support software for breast cancer diagnosis using MRI.
The software mimics an app-style workflow, said Robert Tomek, chief technology officer of Qlarity Imaging.
“There are less clicks to get where you need to go,” Tomek said. “We’re putting what the users want right in front of them.”
The company is also researching other breast imaging areas outside of MR, with plans to develop a single platform for all breast imaging modalities in the future.
In late 2018, ScreenPoint Medical received FDA clearance for Transpara, its AI application to assist radiologists with reading screening 2D mammograms. In March 2020, ScreenPoint received FDA clearance for use with 3D mammograms — the first AI application to be cleared for use with both 2D and 3D mammograms.
The product, which is distributed in the United States, Australia, New Zealand and parts of Asia by Volpara, provides radiologists with a “second set of eyes,” said David Lee, ScreenPoint Medical’s marketing manager.
The company said customers are also eyeing the solution to help them with the backlog of screening exams due to the COVID-19 pandemic.